Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets.
about
CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosisThe compensatory enrichment of sphingosine -1- phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 diabetes mellitus.The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression.Characteristics of coronary artery disease in symptomatic type 2 diabetic patients: evaluation with CT angiography.Diabetes & coronary heart disease: current perspectives.Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosisAngiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice.Interleukin-1-beta and dyslipidemic syndrome as major risk factors for thrombotic complications in type 2 diabetes mellitusCalpains and their multiple roles in diabetes mellitus.High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphateHomocysteine promotes vascular smooth muscle cell migration by induction of the adipokine resistin.Antiatherothrombotic effects of dipeptidyl peptidase inhibitors.QSAR studies in the discovery of novel type-II diabetic therapies.Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages.Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus.Vascular dysfunction in Type 2 diabetes: emerging targets for therapy.The impact of insulin resistance on macrophage death pathways in advanced atherosclerosis.Platelet aggregation is not enhanced in patients with prediabetes.C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.A study of the natural history of diabetic kidney disease (DKD).Relationship between insulin resistance assessed by HOMA-IR and exercise test variables in asymptomatic middle-aged patients with type 2 diabetes.Study on the action of resistin-induced human umbilical vein endothelial cell dysfunction.Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance.Effect of 6 Months of Meditation on Blood Sugar, Glycosylated Hemoglobin, and Insulin Levels in Patients of Coronary Artery Disease.
P2860
Q28729175-BD173617-3F9F-430A-AD11-79620F5A2C65Q30578060-DD00EE22-F6CE-4E1D-A071-CA45A2C978C6Q33586616-2BCA6BE6-AF6E-4F68-8C93-24C952766196Q34353474-04BBD4AD-8BC6-40C9-88B3-37B3E796B2E6Q34530098-B78D6D02-2F22-4C61-AAE1-ABEB00CC86E9Q35721055-E9DF5CFE-DD71-4841-AD98-7F746914FD9DQ36011828-F8B0346D-17DC-4B05-8A81-B61BD68B13C8Q36124082-BD1F1695-36ED-4A88-A5F9-682DA028B7A9Q36524275-1D5335AE-E486-4A93-8A96-227A3D89C6FEQ36587512-C61013EC-79A1-4526-B767-CECA542588C9Q36675894-F455D4AD-B038-4EBB-8C94-E2254F249E3CQ36691031-C623202D-C868-403E-AEAD-07E8763A0751Q37474507-D2A266B0-C33A-4B62-B3E5-C85EA82DC1C3Q38195527-63DFAF3F-9573-4395-9FD2-4B2905E07948Q38630598-0E62ACBD-6AD4-4B0D-880B-623BD1DA5C0AQ40253244-33D735AB-7A83-4343-A9F2-4BD0456EDD79Q40559827-928E357B-258E-4D59-85CE-66DE8290240CQ41121422-09D12863-760C-4349-A6E7-19EAFF549AAFQ41821815-BA015E09-BF42-416E-A3FA-E4E99F1759B5Q43724690-C9343A09-68EC-465B-B93B-4B0C165790ACQ44990813-7EF3BEE3-CDF6-4674-9E6F-C0B82C929FBBQ45271283-E6FED0B4-82F5-4173-875B-B8664CACEC9CQ46418378-DD2B67B5-DE8D-40D3-85F7-BCD39643B14FQ46606032-1B8C10EC-FEA9-44C1-A377-00AC3F9B3098Q50995599-AD9C7035-7521-4861-9A64-AAD0F751B226Q53890133-02EB8A92-1354-4EE3-8DD4-3AFCF70E2450Q54533625-A6E4FE85-2564-41A8-BAB1-5CB61BF6697EQ54578923-4B301E47-414B-4E7B-8EF3-F62455E557E3Q55286644-A8EDC6C4-719E-4B52-9DE5-B3A1FE13EF58
P2860
Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Atherosclerosis in type 2 diab ...... links and therapeutic targets.
@ast
Atherosclerosis in type 2 diab ...... links and therapeutic targets.
@en
type
label
Atherosclerosis in type 2 diab ...... links and therapeutic targets.
@ast
Atherosclerosis in type 2 diab ...... links and therapeutic targets.
@en
prefLabel
Atherosclerosis in type 2 diab ...... links and therapeutic targets.
@ast
Atherosclerosis in type 2 diab ...... links and therapeutic targets.
@en
P2093
P1476
Atherosclerosis in type 2 diab ...... links and therapeutic targets.
@en
P2093
Giancarlo Viberti
Jorge Plutzky
Steven Haffner
P304
P356
10.1016/S1056-8727(02)00202-7
P577
2002-11-01T00:00:00Z